PureTech Health (CHIX:PRTCL) Total Liabilities : £154.01 Mil (As of Dec. 2024)

View and export this data going back to 2015. Start your Free Trial

What is PureTech Health Total Liabilities?

PureTech Health's Total Liabilities for the quarter that ended in Dec. 2024 was £154.01 Mil.

PureTech Health's quarterly Total Liabilities increased from Dec. 2023 (£186.24 Mil) to Jun. 2024 (£215.16 Mil) but then declined from Jun. 2024 (£215.16 Mil) to Dec. 2024 (£154.01 Mil).

PureTech Health's annual Total Liabilities increased from Dec. 2022 (£127.30 Mil) to Dec. 2023 (£186.24 Mil) but then declined from Dec. 2023 (£186.24 Mil) to Dec. 2024 (£154.01 Mil).

PureTech Health Total Liabilities Historical Data

The historical data trend for PureTech Health's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PureTech Health Total Liabilities Chart

PureTech Health Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Total Liabilities

Get a 7-Day Free Trial

250.32

272.12

127.30

186.24

154.01

PureTech Health Semi-Annual Data
	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Total Liabilities	Get a 7-Day Free Trial															127.30	146.25	186.24	215.16	154.01

PureTech Health Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

PureTech Health's Total Liabilities for the fiscal year that ended in Dec. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	32.738	+	(11.605	+	108.194
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0	+	1.472	+	0)
	=	154.01

Total Liabilities	=	Total Assets (A: Dec. 2024 )	-	Total Equity (A: Dec. 2024 )
	=	476.684	-	322.675
	=	154.01

PureTech Health's Total Liabilities for the quarter that ended in Dec. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	32.738	+	(11.605	+	108.194
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0	+	1.472	+	0)
	=	154.01

Total Liabilities	=	Total Assets (Q: Dec. 2024 )	-	Total Equity (Q: Dec. 2024 )
	=	476.684	-	322.675
	=	154.01

PureTech Health Total Liabilities Related Terms

Thank you for viewing the detailed overview of PureTech Health's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

PureTech Health Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PureTech Health PLC (CHIX:PRTCl) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

PRTC:USA PTCHF:USA PRTC:UK 0VQ:Germany

Address

6 Tide Street, Suite 400, Boston, MA, USA, 02210

Website

https://www.puretechhealth.com

PureTech Health PLC, together with its subsidiaries, is a clinical-stage biopharma company developing medicines to modulate the adaptive human system. The company is focused on developing and commercializing differentiated medicines for devastating diseases, including inflammatory, immunological conditions, intractable cancers, lymphatic & gastrointestinal diseases, and neurological and neuropsychological disorders, among others. Its drug development pipeline consists of Deupirfenidone (LYT-100), for the potential treatment of idiopathic pulmonary fibrosis (IPF), LYT-200, SPT-300, an oral drug for depressive disorder, SPT-320, and others. The company's operating segments include Parent Companies & Other, which derives key revenue, Wholly-Owned Programs, and Controlled Founded Entities.

PureTech Health Headlines

No Headlines